{
    "id": "correct_subsidiary_00055_0",
    "rank": 19,
    "data": {
        "url": "https://patents.google.com/patent/FI942359A/en",
        "read_more_link": "",
        "language": "en",
        "title": "FI942359A - Type I and Type II surface antigens related to Staphylococcus epidermidis - Google Patents",
        "top_image": "",
        "meta_img": "",
        "images": [],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": "1991-11-22T00:00:00",
        "summary": "",
        "meta_description": "A process is disclosed for culturing clinical Staphylococcus epidermidis cells that reproducibly enables identification of a limited number of predominant serotypes. Two predominant serotypes common to most clinical cases of S. epidermidis have been identified and are denoted Type I and Type II. A particular polysaccharide surface antigen is associated with each of the Type I and Type II serotypes. The surface antigens can be used to provide active and passive immunization against S. epidermidis infection and to produce a hyperimmune immunoglobulin or antibodies for treatment of S. epidermidis infection.",
        "meta_lang": "en",
        "meta_favicon": "",
        "meta_site_name": "",
        "canonical_link": "https://patents.google.com/patent/FI942359A/en",
        "text": "Type I and Type II surface antigens related to Staphylococcus epidermidis Download PDF\n\nInfo\n\nPublication number\n\nFI942359A\n\nFI942359A FI942359A FI942359A FI942359A FI 942359 A FI942359 A FI 942359A FI 942359 A FI942359 A FI 942359A FI 942359 A FI942359 A FI 942359A FI 942359 A FI942359 A FI 942359A\n\nAuthority\n\nFI\n\nFinland\n\nPrior art keywords\n\ntype\n\nepidermidis\n\nsurface antigens\n\nstaphylococcus epidermidis\n\nserotypes\n\nPrior art date\n\n1991-11-22\n\nApplication number\n\nFI942359A\n\nOther languages\n\nFinnish (fi)\n\nSwedish (sv)\n\nOther versions\n\nFI942359A0 (en\n\nFI111336B (en\n\nInventor\n\nAli Ibrahim Fattom\n\nD Craig Wright\n\nWalter W Karakawa\n\nOriginal Assignee\n\nUnivax Biolog Inc\n\nAli Ibrahim Fattom\n\nD Craig Wright\n\nPriority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)\n\n1991-11-22\n\nFiling date\n\n1994-05-20\n\nPublication date\n\n1994-05-20\n\n1994-05-20 Application filed by Univax Biolog Inc, Ali Ibrahim Fattom, D Craig Wright filed Critical Univax Biolog Inc\n\n1994-05-20 Publication of FI942359A0 publication Critical patent/FI942359A0/en\n\n1994-05-20 Publication of FI942359A publication Critical patent/FI942359A/en\n\n2003-07-15 Application granted granted Critical\n\n2003-07-15 Publication of FI111336B publication Critical patent/FI111336B/en\n\nLinks\n\nEspacenet\n\nGlobal Dossier\n\nDiscuss\n\n241000191963 Staphylococcus epidermidis Species 0.000 title abstract 5\n\n239000000427 antigen Substances 0.000 title abstract 3\n\n102000036639 antigens Human genes 0.000 title abstract 3\n\n108091007433 antigens Proteins 0.000 title abstract 3\n\n208000015181 infectious disease Diseases 0.000 abstract 2\n\n108060003951 Immunoglobulin Proteins 0.000 abstract 1\n\n238000012258 culturing Methods 0.000 abstract 1\n\n150000004676 glycans Chemical class 0.000 abstract 1\n\n230000000521 hyperimmunizing effect Effects 0.000 abstract 1\n\n230000003053 immunization Effects 0.000 abstract 1\n\n238000002649 immunization Methods 0.000 abstract 1\n\n102000018358 immunoglobulin Human genes 0.000 abstract 1\n\n238000000034 method Methods 0.000 abstract 1\n\n229920001282 polysaccharide Polymers 0.000 abstract 1\n\n239000005017 polysaccharide Substances 0.000 abstract 1\n\nClassifications\n\nA—HUMAN NECESSITIES\n\nA61—MEDICAL OR VETERINARY SCIENCE; HYGIENE\n\nA61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES\n\nA61K39/00—Medicinal preparations containing antigens or antibodies\n\nA61K39/02—Bacterial antigens\n\nA61K39/085—Staphylococcus\n\nA—HUMAN NECESSITIES\n\nA61—MEDICAL OR VETERINARY SCIENCE; HYGIENE\n\nA61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS\n\nA61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics\n\nA61P31/04—Antibacterial agents\n\nA—HUMAN NECESSITIES\n\nA61—MEDICAL OR VETERINARY SCIENCE; HYGIENE\n\nA61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS\n\nA61P37/00—Drugs for immunological or allergic disorders\n\nA61P37/02—Immunomodulators\n\nA61P37/04—Immunostimulants\n\nC—CHEMISTRY; METALLURGY\n\nC07—ORGANIC CHEMISTRY\n\nC07K—PEPTIDES\n\nC07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies\n\nC07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria\n\nC07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria\n\nC07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus\n\nC—CHEMISTRY; METALLURGY\n\nC12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING\n\nC12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE\n\nC12P19/00—Preparation of compounds containing saccharide radicals\n\nC12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds\n\nA—HUMAN NECESSITIES\n\nA61—MEDICAL OR VETERINARY SCIENCE; HYGIENE\n\nA61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES\n\nA61K39/00—Medicinal preparations containing antigens or antibodies\n\nLandscapes\n\nHealth & Medical Sciences (AREA)\n\nChemical & Material Sciences (AREA)\n\nLife Sciences & Earth Sciences (AREA)\n\nOrganic Chemistry (AREA)\n\nGeneral Health & Medical Sciences (AREA)\n\nImmunology (AREA)\n\nMedicinal Chemistry (AREA)\n\nEngineering & Computer Science (AREA)\n\nMicrobiology (AREA)\n\nAnimal Behavior & Ethology (AREA)\n\nPharmacology & Pharmacy (AREA)\n\nPublic Health (AREA)\n\nVeterinary Medicine (AREA)\n\nZoology (AREA)\n\nChemical Kinetics & Catalysis (AREA)\n\nGeneral Chemical & Material Sciences (AREA)\n\nWood Science & Technology (AREA)\n\nGenetics & Genomics (AREA)\n\nBiochemistry (AREA)\n\nBioinformatics & Cheminformatics (AREA)\n\nEpidemiology (AREA)\n\nGeneral Engineering & Computer Science (AREA)\n\nMolecular Biology (AREA)\n\nProteomics, Peptides & Aminoacids (AREA)\n\nBiotechnology (AREA)\n\nNuclear Medicine, Radiotherapy & Molecular Imaging (AREA)\n\nMycology (AREA)\n\nBiophysics (AREA)\n\nCommunicable Diseases (AREA)\n\nOncology (AREA)\n\nPeptides Or Proteins (AREA)\n\nMedicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)\n\nPreparation Of Compounds By Using Micro-Organisms (AREA)\n\nAcyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)\n\nMicro-Organisms Or Cultivation Processes Thereof (AREA)\n\nAbstract\n\nA process is disclosed for culturing clinical Staphylococcus epidermidis cells that reproducibly enables identification of a limited number of predominant serotypes. Two predominant serotypes common to most clinical cases of S. epidermidis have been identified and are denoted Type I and Type II. A particular polysaccharide surface antigen is associated with each of the Type I and Type II serotypes. The surface antigens can be used to provide active and passive immunization against S. epidermidis infection and to produce a hyperimmune immunoglobulin or antibodies for treatment of S. epidermidis infection.\n\nFI942359A 1991-11-22 1994-05-20 Method for Preparing a Vaccine Containing a Type I Polysaccharide Antigen of Staphylococcus epidermis and a Hyperimmunoglobulin against the Antigen FI111336B (en)\n\nApplications Claiming Priority (4)\n\nApplication Number Priority Date Filing Date Title US79625291A 1991-11-22 1991-11-22 US79625291 1991-11-22 PCT/US1992/009784 WO1993009811A1 (en) 1991-11-22 1992-11-20 TYPE I AND TYPE II SURFACE ANTIGENS ASSOCIATED WITH $i(STAPHYLOCOCCUS EPIDERMIDIS) US9209784 1992-11-20\n\nPublications (3)\n\nPublication Number Publication Date FI942359A0 FI942359A0 (en) 1994-05-20 FI942359A true FI942359A (en) 1994-05-20 FI111336B FI111336B (en) 2003-07-15\n\nFamily\n\nID=25167715\n\nFamily Applications (1)\n\nApplication Number Title Priority Date Filing Date FI942359A FI111336B (en) 1991-11-22 1994-05-20 Method for Preparing a Vaccine Containing a Type I Polysaccharide Antigen of Staphylococcus epidermis and a Hyperimmunoglobulin against the Antigen\n\nCountry Status (12)\n\nCountry Link US (2) US5866140A (en) EP (1) EP0648127B1 (en) JP (2) JP4087896B2 (en) AT (1) ATE237351T1 (en) AU (1) AU681573B2 (en) CA (1) CA2123811C (en) DE (1) DE69233012T2 (en) DK (1) DK0648127T3 (en) ES (1) ES2198405T3 (en) FI (1) FI111336B (en) NO (1) NO319013B1 (en) WO (1) WO1993009811A1 (en)\n\nFamilies Citing this family (36)\n\n* Cited by examiner, â Cited by third party Publication number Priority date Publication date Assignee Title US5055455A (en) 1988-09-28 1991-10-08 Brigham And Women's Hospital Capsular polysaccharide adhesin antigen, preparation, purification and use US7279162B1 (en) 1990-10-22 2007-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Isolated broadly reactive opsonic immunoglobulin for treating a pathogenic coagulase-negative staphylococcus infection US5955074A (en) * 1990-10-22 1999-09-21 Henry M. Jackson Foundation For The Advancement Of Military Medicine Directed human immune globulin for the prevention and treatment of staphylococcal infections US20080139789A1 (en) * 1990-10-22 2008-06-12 Henry M. Jackson Foundation For The Advancement Of Military Medicine Isolated Broadly Reactive Opsonic Immunoglobulin for Treating a Pathogenic Coagulase-Negative Staphylococcus Infection JP4160633B2 (en) * 1994-09-21 2008-10-01 ãã³ãªã¼ ã¨ã ï¼ã¸ã£ã¯ã½ã³ ãã¡ã¦ã³ãã¼ã·ã§ã³ ãã©ã¼ ã¶ ã¢ããã³ã¹ã¡ã³ã ãªã ããªã¿ãªã¼ ã¡ãã£ã¹ã³ Opsonizing antibodies that react extensively with common staphylococcal antigens US6610293B1 (en) 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria US7250494B2 (en) * 1998-06-15 2007-07-31 Biosynexus Incorporated Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria US7252828B2 (en) 1998-07-15 2007-08-07 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections US9134303B1 (en) 1998-08-25 2015-09-15 Alere Scarborough, Inc. ICT immunoassay for Legionella pneumophila serogroup 1 antigen employing affinity purified antibodies thereto US6824997B1 (en) 1998-09-18 2004-11-30 Binax, Inc. Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies WO2000012132A1 (en) * 1998-08-31 2000-03-09 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation US6692739B1 (en) 1998-08-31 2004-02-17 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation US7030101B2 (en) 1998-09-14 2006-04-18 Nabi Biopharmaceuticals Compositions of Î²-glucans and specific antibodies EP1121135B1 (en) * 1998-09-14 2009-01-28 Nabi Biopharmaceuticals Compositions of beta-glucans and specific immunoglobulins US6936258B1 (en) * 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine GB9924351D0 (en) 1999-10-14 1999-12-15 Brennan Frank Immunomodulation methods and compositions WO2001034809A2 (en) * 1999-11-09 2001-05-17 Glaxo Group Limited Staphylococcus epidermidis nucleic acids and proteins US6703492B1 (en) 1999-11-09 2004-03-09 Smithkline Beecham Corporation Staphylococcus epidermidis nucleic acids and proteins CA2501077C (en) 2002-11-12 2016-06-21 Gerald B. Pier Polysaccharide vaccine for staphylococcal infections WO2004043407A2 (en) 2002-11-12 2004-05-27 The Brigham And Women's Hospital, Inc. Methods and products for treating staphylococcal infections AU2005236068C1 (en) 2004-04-21 2012-08-30 Beth Israel Deaconess Medical Center, Inc. Poly-N-acetyl glucosamine (PNAG/DPNAG)-binding peptides and methods of use thereof EP2305294B1 (en) 2004-09-22 2015-04-01 GlaxoSmithKline Biologicals SA Immunogenic composition for use in vaccination against staphylococcei EP2298341A3 (en) 2004-10-21 2011-07-13 Wyeth LLC Immunogenic compositions of staphylococcus epidermidis polypeptide and polynucleotide antigens US20060134141A1 (en) * 2004-12-14 2006-06-22 Nabi Biopharmaceuticals Glycoconjugate vaccines containing peptidoglycan US20060153857A1 (en) * 2005-01-10 2006-07-13 Nabi Biopharmaceuticals Method of treating staphylococcus aureus infection CA2611023A1 (en) 2005-06-13 2006-12-21 Nabi Biopharmaceuticals Use of panton-valentine leukocidin for treating and preventing staphylococcus infections NZ574057A (en) 2006-06-12 2012-01-12 Glaxosmithkline Biolog Sa Staphylococcal antigen composition comprising an isolated S. aureus type 5 antigen; an isolated S. aureus type 8 antigen; an isolated S. aureus 336 antigen; an isolated S. aureus alpha-toxin antigen; and an isolated Staphylococcal leukocidin antigen US7754225B2 (en) * 2006-07-20 2010-07-13 Glaxosmithkline Biologicals S.A. Method of protecting against staphylococcal infection AU2008280799B2 (en) * 2007-07-23 2013-07-11 Sanofi Pasteur Limited Immunogenic polypeptides and monoclonal antibodies US20110044968A1 (en) * 2008-03-10 2011-02-24 Pharmal N Corporation Compositions for treatment with metallopeptidases, methods of making and using the same RU2532911C2 (en) 2008-07-21 2014-11-20 ÐÐ·Ðµ ÐÑÐ¸Ñ ÑÐ¼ Ð­Ð½Ð´ Ð£Ð¸Ð¼ÐµÐ½'Ð Ð¥Ð¾ÑÐ¿Ð¸ÑÐ°Ð», ÐÐ½Ðº. Methods and compositions described as synthetic beta-1,6-glucosaminoligosaccharides JP2012530785A (en) 2009-06-22 2012-12-06 ã¯ã¤ã¹ã»ã¨ã«ã¨ã«ã·ã¼ Compositions and methods for preparing Staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions WO2010151544A1 (en) 2009-06-22 2010-12-29 Wyeth Llc Immunogenic compositions of staphylococcus aureus antigens JP5914344B2 (en) 2009-10-30 2016-05-11 ããã«ãã£ã¹ ã¢ã¼ã²ã¼ Purification of Staphylococcus aureus type 5 and type 8 capsular saccharides WO2012075428A1 (en) 2010-12-03 2012-06-07 Sanofi Pasteur Limited Composition for immunization against streptococcus pneumoniae CN113730648B (en) * 2021-09-06 2022-11-01 æ¸©å·çå¸ç¹çç©ç§ææéå ¬å¸ Hydrogel combined with staphylococcus epidermidis and application of hydrogel in treatment of wound surfaces\n\nFamily Cites Families (5)\n\n* Cited by examiner, â Cited by third party Publication number Priority date Publication date Assignee Title JPS5452794A (en) * 1977-09-30 1979-04-25 Kousaku Yoshida Extracting of polysacchride from capusle containing epidermis staphylococus US5097020A (en) * 1983-07-05 1992-03-17 The University Of Rochester Immunogenic conjugates FR2619122B1 (en) * 1987-08-03 1990-03-09 Pasteur Institut PROCESS FOR OBTAINING CAPSULAR POLYOSIDES OF STAPHYLOCOCCS, POLYOSIDES OBTAINED, APPLICATIONS OF SUCH POLYOSIDES AND STRAINS FOR IMPLEMENTING THE PROCESS US5055455A (en) * 1988-09-28 1991-10-08 Brigham And Women's Hospital Capsular polysaccharide adhesin antigen, preparation, purification and use US5571511A (en) * 1990-10-22 1996-11-05 The U.S. Government Broadly reactive opsonic antibodies that react with common staphylococcal antigens\n\n1992\n\n1992-11-20 CA CA002123811A patent/CA2123811C/en not_active Expired - Lifetime\n\n1992-11-20 WO PCT/US1992/009784 patent/WO1993009811A1/en active IP Right Grant\n\n1992-11-20 ES ES92924432T patent/ES2198405T3/en not_active Expired - Lifetime\n\n1992-11-20 JP JP50941193A patent/JP4087896B2/en not_active Expired - Lifetime\n\n1992-11-20 AT AT92924432T patent/ATE237351T1/en active\n\n1992-11-20 DK DK92924432T patent/DK0648127T3/en active\n\n1992-11-20 DE DE69233012T patent/DE69233012T2/en not_active Expired - Lifetime\n\n1992-11-20 EP EP92924432A patent/EP0648127B1/en not_active Expired - Lifetime\n\n1992-11-20 AU AU30747/92A patent/AU681573B2/en not_active Expired\n\n1994\n\n1994-05-19 NO NO19941877A patent/NO319013B1/en not_active IP Right Cessation\n\n1994-05-20 FI FI942359A patent/FI111336B/en not_active IP Right Cessation\n\n1994-12-22 US US08/361,821 patent/US5866140A/en not_active Expired - Lifetime\n\n1995\n\n1995-06-07 US US08/472,211 patent/US5961975A/en not_active Expired - Lifetime\n\n2003\n\n2003-12-24 JP JP2003428138A patent/JP4353789B2/en not_active Expired - Lifetime\n\nAlso Published As\n\nPublication number Publication date JP4087896B2 (en) 2008-05-21 FI942359A0 (en) 1994-05-20 EP0648127B1 (en) 2003-04-16 NO941877D0 (en) 1994-05-19 ES2198405T3 (en) 2004-02-01 NO319013B1 (en) 2005-06-06 AU3074792A (en) 1993-06-15 EP0648127A1 (en) 1995-04-19 CA2123811C (en) 2005-07-05 CA2123811A1 (en) 1993-05-27 DE69233012T2 (en) 2003-11-06 EP0648127A4 (en) 1995-06-14 US5866140A (en) 1999-02-02 FI111336B (en) 2003-07-15 ATE237351T1 (en) 2003-05-15 AU681573B2 (en) 1997-09-04 DE69233012D1 (en) 2003-05-22 NO941877L (en) 1994-06-16 US5961975A (en) 1999-10-05 JPH07508498A (en) 1995-09-21 DK0648127T3 (en) 2003-05-19 JP2004155789A (en) 2004-06-03 JP4353789B2 (en) 2009-10-28 WO1993009811A1 (en) 1993-05-27\n\nSimilar Documents\n\nPublication Publication Date Title\n\nLegal Events\n\nDate Code Title Description 2010-07-14 PC Transfer of assignment of patent\n\nOwner name: GLAXOSMITHKLINE BIOLOGICALS S.A.\n\nFree format text: GLAXOSMITHKLINE BIOLOGICALS S.A.\n\n2012-12-20 MA Patent expired"
    }
}